全文获取类型
收费全文 | 250篇 |
免费 | 5篇 |
专业分类
儿科学 | 39篇 |
妇产科学 | 32篇 |
基础医学 | 23篇 |
口腔科学 | 2篇 |
临床医学 | 11篇 |
内科学 | 58篇 |
皮肤病学 | 17篇 |
神经病学 | 4篇 |
外科学 | 24篇 |
综合类 | 3篇 |
预防医学 | 25篇 |
眼科学 | 5篇 |
药学 | 9篇 |
肿瘤学 | 3篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2016年 | 1篇 |
2015年 | 3篇 |
2014年 | 1篇 |
2013年 | 1篇 |
2012年 | 4篇 |
2010年 | 5篇 |
2009年 | 6篇 |
2008年 | 2篇 |
2007年 | 2篇 |
2006年 | 3篇 |
2005年 | 1篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1999年 | 6篇 |
1998年 | 3篇 |
1997年 | 4篇 |
1996年 | 2篇 |
1995年 | 5篇 |
1994年 | 2篇 |
1993年 | 10篇 |
1992年 | 3篇 |
1990年 | 3篇 |
1989年 | 5篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1985年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1969年 | 1篇 |
1959年 | 6篇 |
1958年 | 23篇 |
1957年 | 26篇 |
1956年 | 32篇 |
1955年 | 28篇 |
1954年 | 25篇 |
1953年 | 2篇 |
1952年 | 1篇 |
1950年 | 1篇 |
1949年 | 10篇 |
1948年 | 5篇 |
1947年 | 1篇 |
排序方式: 共有255条查询结果,搜索用时 15 毫秒
251.
252.
J.P. MICHA B.H. GOLDSTEIN M.A. RETTENMAIER M. GENESEN† C. GRAHAM K. BADER K.L. LOPEZ M. NICKLE & J.V. BROWN III 《International journal of gynecological cancer》2007,17(4):771-776
The purpose of this study was to assess the response rate and toxicity of paclitaxel, carboplatin, and bevacizumab (PCB) primary induction therapy for the treatment of advanced-stage ovarian carcinoma. Twenty patients were treated with paclitaxel (175 mg/m(2)), carboplatin (AUC of 5 IV), and bevacizumab (15 mg/kg) of body weight; q21 days for six cycles. Bevacizumab was administered at cycles two through six. Patients received 116 cycles of PCB chemotherapy (median = 6, range 2-6) and were evaluable for toxicity assessment. Grade 3 and 4 neutropenia developed in 23.3% and 25% of cycles, with no incidence of grades 3/4 thrombocytopenia or anemia. Prior to cycle six, one patient was removed from the study due to grade 3 neuropathy and another patient was excluded due to clinical deterioration. There was no incidence of gastrointestinal perforations, and only two patients demonstrated grade 3 hypertension (HTN). No grade 4 HTN was observed. Eighteen patients were evaluated for response following induction therapy. Six demonstrated a complete response (30%) and ten exhibited a partial response (50%), resulting in a total response rate of 80%. One patient exhibited stable disease (5%), and one demonstrated disease progression (5%). The lack of bowel perforations and wound complications should mitigate some concerns regarding these side effects. This study suggests that first-line treatment with PCB can be safely administered to previously untreated advanced-stage ovarian carcinoma patients. The favorable toxicity results and reasonable response rate warrant additional study in a larger patient population. 相似文献
253.
B. SHEN F. H. REMZI I. C. LAVERY R. LOPEZ E. QUEENER L. SHEN J. GOLDBLUM & V. W. FAZIO 《Alimentary pharmacology & therapeutics》2009,29(5):519-526
Background Crohn's disease (CD) of the pouch can develop in patients with ileal pouch-anal anastomosis (IPAA). Scant data are available on the treatment of this disease entity.
Aim To evaluate efficacy and safety of adalimumab in treating CD of the ileal pouch.
Methods From June 2007 to June 2008, 17 IPAA patients with inflammatory ( n = 10), fibrostenotic ( n = 2) or fistulizing ( n = 5) CD of the pouch treated with adalimumab were evaluated. Inclusion criteria were CD of the pouch who failed medical therapy and were otherwise qualified for permanent pouch diversion or excision. All qualified patients received the standard dosing regimen of subcutaneous injection adalimumab (160 mg at week 0, 80 mg at week 1, and 40 mg every other week thereafter). Complete clinical response was defined as resolution of symptoms. Partial clinical response was defined as improvement in symptoms. Endoscopic inflammation before and after therapy was recorded, using the Pouchitis Disease Activity Index (PDAI) endoscopy subscores.
Results The median age was 36 years with 12 patients (70.6%) being male. At 4 weeks, seven patients (41.2%) had a complete symptom response and 6 (35.3%) had a partial response. There was also a significant improvement in the PDAI endoscopy subscores at week 4 ( P < 0.05). At the last follow-up (median of 8 weeks), eight patients (47.1%) had a complete symptom response and 4 (23.5%) had a partial response. Four patients (23.6%) developed adverse effects. Three patients (17.7%) eventually had pouch failure after failing to respond to adalimumab therapy.
Conclusion Adalimumab appeared to be well-tolerated and efficacious in treating CD of the pouch in this open-labelled induction study. 相似文献
Aim To evaluate efficacy and safety of adalimumab in treating CD of the ileal pouch.
Methods From June 2007 to June 2008, 17 IPAA patients with inflammatory ( n = 10), fibrostenotic ( n = 2) or fistulizing ( n = 5) CD of the pouch treated with adalimumab were evaluated. Inclusion criteria were CD of the pouch who failed medical therapy and were otherwise qualified for permanent pouch diversion or excision. All qualified patients received the standard dosing regimen of subcutaneous injection adalimumab (160 mg at week 0, 80 mg at week 1, and 40 mg every other week thereafter). Complete clinical response was defined as resolution of symptoms. Partial clinical response was defined as improvement in symptoms. Endoscopic inflammation before and after therapy was recorded, using the Pouchitis Disease Activity Index (PDAI) endoscopy subscores.
Results The median age was 36 years with 12 patients (70.6%) being male. At 4 weeks, seven patients (41.2%) had a complete symptom response and 6 (35.3%) had a partial response. There was also a significant improvement in the PDAI endoscopy subscores at week 4 ( P < 0.05). At the last follow-up (median of 8 weeks), eight patients (47.1%) had a complete symptom response and 4 (23.5%) had a partial response. Four patients (23.6%) developed adverse effects. Three patients (17.7%) eventually had pouch failure after failing to respond to adalimumab therapy.
Conclusion Adalimumab appeared to be well-tolerated and efficacious in treating CD of the pouch in this open-labelled induction study. 相似文献
254.
STEPHANE BERNARDINI GERARD-L. ADESSI CLAUDE BILLEREY EVELYNE CHEZY JEAN-PIERRE CARBILLET HUGUES BITTARD 《The Journal of urology》1999,162(4):1496-1501
PURPOSE: Mutations of p53 tumor suppressor gene and nuclear accumulation of p53 protein are common in bladder tumors. The prognostic significance of p53 alterations in bladder tumors has not been established. The aim of the present study was to evaluate an immunohistochemical (IHC) method for the routine determination of p53 protein overexpression in human bladder tumors and to determine the relation between nuclear accumulation of p53 with the traditional prognostic indicators and patient survival. MATERIALS AND METHODS: 104 transitional cell carcinomas of the bladder were analyzed simultaneously by immunohistochemistry for p53 protein overexpression and direct DNA sequencing for p53 gene mutations. RESULTS: The overexpression of p53 protein was reported in 30.8% of the cases and mutations of p53 gene in 23.0%. A significant association was observed between p53 alterations established either by IHC or direct DNA sequencing and stage (p<0.0001), grade (p<0.001), vascular invasion (p = 0.0005), DNA ploidy (p = 0.0002) and carcinoma in situ (p<0.0001). The correlation between the p53 gene mutations and p53 nuclear reactivity as detected by IHC was highly significant (p<0.0001). Univariate statistical analysis showed that the expression of p53 was significantly correlated to poor prognosis (p<0.0001). However, in multivariate analysis, only stage was significantly correlated to prognosis (p<0.0001). CONCLUSIONS: The IHC method was highly sensitive and specific and simple to apply for the routine examination of p53 overexpression in bladder tumors. However, overexpression of p53 as determined immunohistochemically, does not appear to have a better predictive prognostic value than stage in bladder tumors. 相似文献
255.